Arbekacin Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Arbekacin is a semi-synthetic derivative of dibekacin useful in the treatment of
bacterial infections. This aminoglycoside is active against a broad spectrum of
bacteria, including some of the gentamycin-, kanamycin-, and tobramycin-resistant
pathogens. Compared to amikacin and dibekacin, ototoxicity is reportedly milder.
Definition
ChEBI: A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring.
Antimicrobial activity
The 1-N-(4-amino-2-hydroxybutyryl) derivative of dibekacin,
to which it bears the same relation as amikacin bears to kanamycin
A. Supplied as the sulfate.
Activity and stability to aminoglycoside-modifying enzymes
are comparable with those of amikacin. It is active against
many strains of methicillin-resistant Staph. aureus, either alone
or in combination with β-lactam or other agents. Synergy with
ampicillin has been observed for high-level gentamicin- and
vancomycin-resistant enterococci.
A 3 mg/kg intravenous dose achieved a peak concentration
of c. 8 mg/L after 1 h. The plasma half-life is about 2 h and
protein binding 3–12%.
About 85% of the dose can be recovered from urine over
48 h. It is retained in renal failure, but moderately well removed
by hemodialysis with a plasma half-life of 2–4 h. Peak concentrations
of 10.9 mg/L and trough concentrations of 1.7 mg/L
have been reported in patients treated for MRSA infection
where C
max:MIC ratios of >25 and AUC:MIC ratios of >186
were associated with improved cure rates, and both Cmin and
AUC were associated with the incidence of nephrotoxicity.
Toxicity and side effects are typical of the aminoglycoside
class. It is used in severe infection cause by susceptible microorganisms,
but is not widely available.
Arbekacin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
